Redhill Biopharma shares surge 20.39% intraday as RHB-102 progresses in treating GLP-1-related gastrointestinal side effects, with Phase 2 trial planned in 2026.

Redhill Biopharma surged 20.39% intraday, driven by the company's announcement of a planned 2026 Phase 2 trial for RHB-102 in addressing GLP-1 receptor agonist-related gastrointestinal side effects. The drug candidate previously demonstrated positive results in Phase 3 trials for gastroenteritis/ gastritis and Phase 2 trials for diarrhea-predominant irritable bowel syndrome, leveraging decades of clinical use history for the active ingredient, ondansetron. Redhill Biopharma specializes in gastrointestinal and infectious disease therapies, with marketed products including Talicia for Helicobacter pylori eradication. The company's pipeline emphasizes innovative treatments targeting unmet medical needs in gastroenterology.